OBJECTIVE: To assess whether knowledge of insurance implications influenced uptake of genetic testing by participants in a research study of the causes of colorectal cancer. DESIGN, SETTING AND PARTICIPANTS: Analysis of uptake of genetic testing by participants in the population-based Victorian Colorectal Cancer Family Study during two periods: from 1999 to 2003, when participants were not informed of any potential effect of genetic testing conducted during the study on their eligibility for new insurance policies; and from 2003 to 2006, when the protocol was changed to provide participants with information on the potential effect of genetic testing on insurance eligibility. MAIN OUTCOME MEASURE: Uptake of genetic testing for germline mutations in DNA mismatch repair (MMR) genes at a family cancer clinic. RESULTS: The proportion of participants who declined genetic testing among those informed of insurance implications was more than double the proportion among those without this knowledge (29/59 [49%] v 9/47 [19%]; P = 0.002). This difference could not be explained statistically by adjusting for measured putative predictors. CONCLUSION: Identification of people with a mutation in an MMR gene has clinical importance, and such screening may be a cost-effective way to reduce the burden of colorectal cancer in the community. If people are choosing not to obtain genetic information because of how it will affect their eligibility for insurance, reforms to existing insurance practices are indicated.
OBJECTIVE: To assess whether knowledge of insurance implications influenced uptake of genetic testing by participants in a research study of the causes of colorectal cancer. DESIGN, SETTING AND PARTICIPANTS: Analysis of uptake of genetic testing by participants in the population-based Victorian Colorectal Cancer Family Study during two periods: from 1999 to 2003, when participants were not informed of any potential effect of genetic testing conducted during the study on their eligibility for new insurance policies; and from 2003 to 2006, when the protocol was changed to provide participants with information on the potential effect of genetic testing on insurance eligibility. MAIN OUTCOME MEASURE: Uptake of genetic testing for germline mutations in DNA mismatch repair (MMR) genes at a family cancer clinic. RESULTS: The proportion of participants who declined genetic testing among those informed of insurance implications was more than double the proportion among those without this knowledge (29/59 [49%] v 9/47 [19%]; P = 0.002). This difference could not be explained statistically by adjusting for measured putative predictors. CONCLUSION: Identification of people with a mutation in an MMR gene has clinical importance, and such screening may be a cost-effective way to reduce the burden of colorectal cancer in the community. If people are choosing not to obtain genetic information because of how it will affect their eligibility for insurance, reforms to existing insurance practices are indicated.
Authors: S G Nicholls; B J Wilson; S M Craigie; H Etchegary; D Castle; J C Carroll; B K Potter; L Lemyre; J Little Journal: Genome Date: 2013-08-31 Impact factor: 2.166
Authors: Louisa Flander; Andrew Speirs-Bridge; Alison Rutstein; Heather Niven; Aung Ko Win; Driss Ait Ouakrim; John L Hopper; Finlay Macrae; Louise Keogh; Clara Gaff; Mark Jenkins Journal: J Genet Couns Date: 2013-06-09 Impact factor: 2.537
Authors: Aung Ko Win; Noralane M Lindor; Ingrid Winship; Katherine M Tucker; Daniel D Buchanan; Joanne P Young; Christophe Rosty; Barbara Leggett; Graham G Giles; Jack Goldblatt; Finlay A Macrae; Susan Parry; Matthew F Kalady; John A Baron; Dennis J Ahnen; Loic Le Marchand; Steven Gallinger; Robert W Haile; Polly A Newcomb; John L Hopper; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2013-02-05 Impact factor: 13.506
Authors: Joanne Soo-Min Kim; Peter C Coyte; Michelle Cotterchio; Louise A Keogh; Louisa B Flander; Clara Gaff; Audrey Laporte Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-15 Impact factor: 4.254
Authors: Louise A Keogh; Douglass Fisher; Sherri Sheinfeld Gorin; Sheri D Schully; Jan T Lowery; Dennis J Ahnen; Judith A Maskiell; Noralane M Lindor; John L Hopper; Terrilea Burnett; Spring Holter; Julie L Arnold; Steven Gallinger; Mercy Laurino; Mary-Jane Esplen; Pamela S Sinicrope Journal: J Community Genet Date: 2013-05-24
Authors: Anita M Y Goh; Edmond Chiu; Olga Yastrubetskaya; Cheryl Erwin; Janet K Williams; Andrew R Juhl; Jane S Paulsen Journal: Genet Test Mol Biomarkers Date: 2013-01-04